


Please type a plus sign (+) inside this box → 


PTO/SB/08A (10-98)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1442A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/787,367	
			Filing Date	02/26/2004	
			First Named Inventor	GRAUPE	
			Group Art Unit	1628	
			Examiner Name	Coppins, Janet	
Sheet	1	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
JLC		4,927,809		STUBER, et al.	05-22-1990	
		5,424,325		ANDO, et al.	08-19-1995	
		5,486,623		ZIMMERMAN, et al.	01-23-1996	
		5,498,616		MALLANO, et al.	03-12-1996	
		5,847,195		BEMIS, et al.	12-08-1998	
		5,852,007		CHATTERJEE, et al.	12-22-1998	
		5,874,424		BATCHELOR, et al.	02-23-1999	
		5,998,990		RAMAMURTHY, et al.	12-07-1999	
		6,004,833		SPRUCE, et al.	12-21-1999	
		6,022,881		SCARBOROUGH, et al.	02-08-2000	
		6,114,310		CHAMBERLAND, et al.	09-05-2000	
		6,124,333		MILLER, et al.	12-26-2000	
		6,255,453		GYORKOS	07-03-2001	
		6,353,017		ALTMAN, et al.	03-05-2002	
		6,455,502		BRYANT, et al.	09-24-2002	
		6,478,028		BRYANT, et al.	11-05-2002	
		6,482,382		GRAUPE, et al.	12-10-2002	
JLC		6,508,793		BUYSSE	01-14-2003	
		6,576,630		LINK, et al.	06-10-2003	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>			
JLC		EP	EP 0272871	KRANTZ, et al.	06-29-1988	
		EP	EP 0291234	EDWARDS, et al.	11-17-1998	
		EP	EP 0355572	PAQUES, et al.	02-28-1990	
		EP	EP 0376012	ALBRIGHT, et al.	07-04-1990	
		EP	EP 0419683	HARA, et al.	04-03-1991	
		EP	EP 0536399	OKUBO, et al.	04-01-1993	
		EP	EP 0652009	DOVEY, et al.	10-05-1995	
		EP	EP 0754454	KOBAYASHI, et al.	01-22-1997	
JLC		JP	JP 08182199	RYOICHI, et al.	07-12-1994	
		JP	JP 42009133	IRIKURA, et al.	05-06-1967	

Examiner Signature		Date Considered	7/1/05
-----------------------	---	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.









Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-95)  
 Approved for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/787,367
			Filing Date	02/26/2004
			First Named Inventor	GRAUPE
			Group Art Unit	1826
			Examiner Name	Coppins, Janet
			Attorney Docket Number	USAV2001/0143 - US - CNT
Sheet	6	of	13	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JAC		ADAMS, et al., Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids, Bioorganic & Medicinal Chemistry Letters, 8: 333-338 (1998).	
		ASHWORTH, et al., 4-Cyanomiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV, Bioorganic & Med. Chem. Letters, B, Oxford, 6(22):2745-2748 (1995).	
		BERGEMAN, et al., Studies on the reactivity of .alpha.-cyano.alpha.-isocyano alkanoates. Versatile synthons for the assembly of imidazoles, Helv.Chim. ACTA, 82(6):509-518 (1999).	
		BILLSON, et al., The Design and Synthesis of Inhibitors of the Cysteine, Bioorg. Med. Chem. Lett. vol. 8, pp. 993-998, 1998	
		BROMME, et al., Potent Inactivation of Cathepsins B and L, Biol. Chem. Hoppe-Seyler. vol. 376, No. 5, pp. 343-347, 1994.	
		CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain I, Journal of Medicinal Chemistry, vol. 41, No. 15, p: 2663-2668 (1998).	
		COHEN, et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, Journal of Neuroimmunology, 98: 29-38 (1999).	
		DUFOUR, et al., Engineering nitrile hydratase activity into a cysteine protease by a single mutation, Biochemistry, US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995).	
		EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl a-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole, Journal of American Chemical Society, vol. 114, No. 6, p 1654-1883 (1992).	
ELC		EVOLI, et al., abstract only, Drugs, 1996, 52(5), 682-70	

Examiner Signature	<i>Janet L. Coppins</i>	Date Considered	7/1/00
--------------------	-------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-98)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/787,367
				Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1628
				Examiner Name	Coppins, Janet
Sheet	7	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gll		GOUR-SALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group into other functionalities via the papainnitrile thiomidate ester adduct, Can. J. of Chem, CA, National Research Council, Ottawa, 69(8):1288-1297 (1991).	
		HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9: 241-251 (2000).	
		HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophys. Acta, vol. 1035, No. 1, 1990, pp. 62-70.	
		HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and (achalasias) methyl ketones as inhibitors of the enzyme, Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett, 5(4) 393-396 (1995).	
		HEITMILLER, R.F., abstract only., Semin. Thorac. Cardiovasc. Surg., 1999, 11(1), 41-6	
		KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha-(acylamino) nitriles and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990).	
		KHAMASHTA, et al., Expert Opin. Investig. Drugs, 2000, 9(7), 1581-93.	
		KRANTZ, et al., Peptidyl (Acylalkoxy)methyl Ketones and the Quiescent, Biochemistry, vol. 30, pp. 4678-4687, 1991	
		LEVY, E.G., Baillieres Clin. Endocrinol. Metab., 1997, 11(3) 585-595	
gll		Li, et al., Aminocyclopentylidene-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archives of Biochem. and Bioph., 323(1)148-154 (1995).	

Examiner Signature	<i>Janet A. Coppins</i>	Date Considered	7/1/05
--------------------	-------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language translation is attached.

Burdan Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/99, OMB 0651-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/787,367		
		Filing Date	02/28/2004		
		First Named Inventor	GRAUPE		
		Group Art Unit	1828		
		Examiner Name	Coppins, Janet		
Sheet	8	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gll		LIPSHUTZ, et al., Chiral induction in originally racemic amino acids via 5-aryl and 5-acyloxyaminooxazoles, <i>Isr. J. Chem.</i> 27(1):49-55 (1988), abstract.	
		LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, <i>J. Am. Chem. Soc.</i> , 105(28):7703-7713 (1983).	
		LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, <i>J. Am. Chem. Soc.</i> , 112(19):7032-7041 (1990).	
		MARQUIS, et al., Potent dipeptidylkallikrein inhibitors of the cysteine protease cathepsin, <i>Chemical Abstracts</i> , 74:581-588 (1999).	
		MCMATH, et al., Direct dialkylation of peptide nitriles. Application of the synthesis of 1-aminocyclopropane-1-carboxylic acid (Acc)-containing dipeptides, <i>Bull. Soc. Chim. Fr.</i> 134(1):105-110 (1997).	
		MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives, <i>J. Med. Chem.</i> , 29: 333-341 (1986).	
		MOSER, et al., 130 Poly (dipeptamidinium)-Salze: definition und methoden zur preparativen herstellung, poly (dipeptamidinium) salts: definition and methods of preparation, <i>Helvetica Chimica Acta</i> , CH, Verlag, Basel 69:1224-1262 (1986).	
		NIPPON, K., Patent Abstracts of Japan, Publication No. 63301868, 013(197)(1988), abstract.	
		NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids, <i>Tetrahedron</i> , 46(24):8627-8290 (1990).	
gll		OGILVIE, et al., Peptidomimetic inhibitors of the human cytomegalovirus protease, <i>Journal of Medicinal Chemistry</i> vol. 40 No. 25 (1997).	

Examiner Signature		Date Considered	7/1/05
-----------------------	---	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-98)  
 Approved for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/787,367
				Filing Date	02/26/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1626
				Examiner Name	Coppins, Janet
Sheet	9	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
OK		PICKEN, et al., Inhibition of bovine cathepsin B by amino acid-derived nitriles, Biochemical Society Transactions, vol. 18, No. 2, p:316 (1990).	
		PLIURA, et al., Comparative behavior of calpain and cathepsin B, Biochem. J. vol. 288, pp. 759-762, 1992	
		POLMAN, et al., Drug treatment of multiple sclerosis, BMJ, 321: 19-26 (2000).	
		RIESE, et al., Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 357-368 (Apr. 1996).	
		SMITH, et al., New Inhibitors of Cysteine Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4429-4431, 1988	
		SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofunctionalized enamines and monofunctionalized methyl ketone derivatives from thioamides via episulfides and thioiminium salts, Tetrahedron Lett, 29:19 2295-2298 (1988).	
		SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxyacyl) aminoacetonitriles, Chem. and Pharm. Bull. (Tokyo) (1968), 16(8), 1417-32.	
		SUZUE, et al., Studies on Hepatic Agents, Chem. Pharm. Bull. vol. 16, No. 8, pp. 1417-1432, Aug. 1968.	
		SUZUKI, et al., Synthesis of 2-Aryl-4(3-thienyl)imidazole Derivatives with Antiinflammatory Properties .sup.1), Chem. Pharm. Bull, 34(8): 3111-3120 (1986).	
OK		TAO, et al., Inhibition of Calpain By Peptidyl Heterocycles, Bioorganic & Medicinal Chemistry Letters, 8:24 3009-3112 (1998).	

Examiner Signature	<i>Janet A. Coppins</i>	Date Considered	7/1/05
--------------------	-------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/99, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/787,367		
		Filing Date	02/28/2004		
		First Named Inventor	GRAUPE		
		Group Art Unit	1626		
		Examiner Name	Coppins, Janet		
Sheet	10	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gll		THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986).	
		TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl $\alpha$ -Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3492-3502 (1994).	
		VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitriles, Stud. Univ. Babes-Bolyai, Ser. Chem., 13(2):31-5 (English abstract of article in Romanian) (1968).	
		VARGHESE, The structure and resonance Raman spectra-structure correlations for methoxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester, Can. J. Chem., 64(6):1688-1673 (1986).	
		YAMADA, et al., Studies of unusual amino acids and their peptides. IX. The synthetic study of bottomycins B1 and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract.	
gll		, Derwent Abstract of Japanese Patent Application 06-192199, (Jul. 12, 1994).	

Examiner Signature	<i>Janet L. Coppins</i>	Date Considered	7/1/05
--------------------	-------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-86)  
 Approved for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/787,367	
			Filing Date	02/26/2004	
			First Named Inventor	GRAUPE	
			Group Art Unit	1626	
			Examiner Name	Coppins, Janet	
Sheet	11	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		09/927,188		CAI, et al.	08-10-2001	
		09/927,324		BUTLER, et al.	08-10-2001	
		09/828,122		BREITENBUCHER, et al.	08-10-2001	
		08/848,214		GU, et al.	09-05-2001	
		10/042,585		QUIBELL, et al.	11-16-2001	
		10/148,612		OHMOTO, et al.	08-21-2002	
		10/148,613		OHMOTO, et al.	08-28-2002	
		10/181,713		OHMOTO, et al.	07-22-2002	
		10/181,799		OHMOTO, et al.	07-23-2002	
		10/231,425		BUXTON, et al.	08-28-2002	
		10/258,512		BEKKALI, et al.	09-27-2002	
		10/258,053		CUMMINGS, et al.	10-17-2002	
		10/275,583		COWEN, et al.	11-07-2002	
		10/279,424		BEKKALI, et al.	10-24-2002	
		10/468,385		QUIBELL, et al.	01-08-2004	
		6,016,791		GYORKOS, et al.	01-18-2000	
		6,808,057		CYWIN, et al.	06-18-2003	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
		JP	JP 2001-011037		SATO, et al.	01-16-2001	
		JP	JP 2001-055366		SATO, et al.	02-27-2001	
		WO	WO00/59881		SINGH, et al.	10-12-2000	
		WO	WO01/09169		SINGH, et al.	02-08-2001	
		WO	WO02/057248		QUIBELL, et al.	07-25-2002	
		WO	WO02/057249		QUIBELL, M	07-25-2002	
		WO	WO02/057270		QUIBELL, M	07-25-2002	
		WO	WO02/096892		OHMOTO, et al.	05-30-2002	
		WO	WO02/100849		HICKEY, et al.	12-19-2002	
		WO	WO02/20485		BEKKALI, et al.	03-14-2002	

Examiner Signature	<i>Janet Coppins</i>	Date Considered	7/1/05
--------------------	----------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐PTO/SB/088 (10-99)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/787,387
				Filing Date	02/28/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1828
				Examiner Name	Coppins, Janet
Sheet	12	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gfc		CHAPMAN, et al., Emerging Roles for Cysteine Proteases in Human Biology, Ann. Rev. Physiol.; 1997; 59; pp.63-88.	
		DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, Immunity; 1999; 10; pp.197-205.	
		FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cyclic Alkoxyketone Inhibitors of Cathepsin K., Bioorg. Med. Chemm. Lett.; 2001; 11(2); pp.189-202.	
		FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cysteine Protease Cathepsin K., Bioorg. Med. Chem. Lett.; 2001; 11(2); pp.195-198.	
		GREENSPAN, et al., Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, J. Med. Chem.; 2001; 44; pp.4524-4534.	
		LOWE, et al., Kinetic Specificity in Papain-catalyzed Hydrolyses, Biochem. J.; 1971; 124(1); pp.107-115.	
		MACIEWICZ, et al., A comparison of Four Cathepsins (B,L,N and S) with Collagenolytic Activity From Rabbit Spleen, Biochem J.; 1998; 256; pp.433-440.	
		MARQUIS, et al., Azasone-based Inhibitors of Human and Rat Cathepsin K., J. Med. Chem.; 2000; 44(8); pp.1380-1395.	
		NAKAGAWA, et al., Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-induced Arthritis in Cathepsin S-null Mice, Immunity; 1999; 10; pp.207-217.	
gfc		OTTO, et al., Cysteine Proteases and their Inhibitors, Chem. Rev.; 1997; 97; pp.133-171.	

Examiner Signature		Date Considered	7/1/05
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/787,367
				Filing Date	02/28/2004
				First Named Inventor	GRAUPE
				Group Art Unit	1826
				Examiner Name	Coppins, Janet
Sheet	13	of	13	Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gic		SHI, et al., Molecular Cloning and Expression of Human Alveolar Macrophage Cathepsin S, an Elastolytic Cysteine Protease, J. Biol. Chem.; 1992; 267; pp.7258-7262.	
gic		SINGH, et al., beta-lactams as Enzyme Inhibitors., IDrugs; 2000; 3(5); pp.512-517.	
gic		VILLADANGOS, et al., Cathepsin S Activity Regulates Antigen Presentation and Immunity, J. Clin. Invest.; 1998; 101(10); pp.2351-2363.	

Examiner Signature	<i>gic</i>	Date Considered	7/11/05
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.